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ABSTRACT
During hepatitis C virus (HCV) infection, broadly neutralizing antibody (bNAb) responses targeting E1E2 envelope glycopro-
teins are generated in many individuals. It is unclear if these antibodies play a protective or a pathogenic role during chronic
infection. In this study, we investigated whether bNAb responses in individuals with chronic infection were associated with dif-
ferences in clinical presentation. Patient-derived purified serum IgG was used to assess the breadth of HCV E1E2 binding and
the neutralization activity of HCV pseudoparticles. The binding and neutralization activity results for two panels bearing viral
envelope proteins representing either an intergenotype or an intragenotype 1 group were compared. We found that the HCV
load was negatively associated with strong cross-genotypic E1E2 binding (P 0.03). Overall, we observed only a modest correla-
tion between total E1E2 binding and neutralization ability. The breadth of intergenotype neutralization did not correlate with
any clinical parameters; however, analysis of individuals with genotype 1 (gt1) HCV infection (n 20), using an intragenotype
pseudoparticle panel, found a strong association between neutralization breadth and reduced liver fibrosis (P 0.006). A broad
bNAb response in our cohort with chronic infection was associated with a single nucleotide polymorphism (SNP) in theHLA-
DQB1 gene (P 0.038), as previously reported in a cohort with acute disease. Furthermore, the bNAbs in these individuals tar-
geted more than one region of E2-neutralizing epitopes, as assessed through cross-competition of patient bNAbs with well-char-
acterized E2 antibodies. We conclude that the bNAb responses in patients with chronic gt1 infection are associated with lower
rates of fibrosis and host genetics may play a role in the ability to raise such responses.
IMPORTANCE
Globally, there are 130 million to 150 million people with chronic HCV infection. Typically, the disease is progressive and is a
major cause of severe liver cirrhosis and hepatocellular carcinoma.While it is known that neutralizing antibodies have a role in
spontaneous clearance during acute infection, little is known about their role in chronic infection. In the present work, we inves-
tigated the antibody response in a cohort of chronically infected individuals and found that a broadly neutralizing antibody re-
sponse is protective and is associated with reduced levels of liver fibrosis and cirrhosis. We also found an association between
SNPs in class II HLA genes and the presence of a broadly neutralizing response, indicating that antigen presentationmay be im-
portant for the production of HCV-neutralizing antibodies.
Hepatitis C virus (HCV) is a significant cause of livermorbidityand mortality worldwide (1). In the majority (75%) of those
infected, the infection proceeds to a chronic infection (2). Symp-
tomatic acute HCV infection is rare; therefore, HCV has the po-
tential to spread undetected among those at risk. In countries with
a high prevalence, a poor health care infrastructure and a lack of
fundingmake eradication of HCV unlikely through curative ther-
apies alone (1, 3). Thus, effective preventative strategies are
needed to achieve the global eradication of the virus (4).
Antibodies targeting the HCV envelope glycoproteins E1 and
E2 can contribute significantly to viral clearance inHCV infection
(5, 6). These proteins are responsible for virus attachment and
entry into host cells through interaction with the receptors SR-B1,
CD81, Claudin, and Occludin (7–10). Previous observational
studies have shown the rapid onset of anti-HCV antibodies to be
associated with a higher likelihood of clearance (11). More re-
cently, it has been proposed that the development of a profile
consisting of antibodies capable of neutralizing diverse HCV
strains (a broadly neutralizing antibody [bNAb]profile) predicts
the clearance of acute infection in a cohort infected with genotype
1a (gt1a) HCV (12). Further studies have suggested that bNAbs
may be able to control the levels of virus and contribute to clear-
ance even after infection has become established (13). In one case
in which a chronically infected patient spontaneously cleared
HCV, a bNAb response was initially generated, and subsequently,
T cell activity was restored and the infection was resolved (5).
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Only a small number of individuals with bNAbs have been
studied in detail, but there is little information on the regions of
the E1E2 glycoproteins that are preferentially targeted by these
antibodies. This has largely involved epitope mapping of patient-
derivedmonoclonal antibodies (MAbs) (14–16). Human neutral-
izing and nonneutralizing MAbs have been used to identify dis-
tinct immunogenic domains of E1E2 (15, 17–21). However, in
vivo, a polyclonal response which may target multiple regions of
the envelope proteins is generated. A recent study demonstrated
that antibodies from some HCV-infected individuals largely tar-
get one immunogenic domain, whereas other individuals produce
antibody responses to multiple domains (21). The importance of
the interplay of antibodies binding different epitopes has not been
fully explored, although there are conflicting reports of some an-
tibodies conferring additive or interfering effects on virus neutral-
ization (22, 23).
While diverse HCV strains are usually categorized by genotype
(gt), this categorization does not correlate well with sensitivity to
neutralization by MAbs (24, 25). The genetic diversification of
HCV both within and between hosts introduces the potential for
HCV to escape from monoclonal bNAbs, with several studies re-
porting that naturally occurring, single amino acid mutations
confer the ability to escape (18, 26). The recently published E2
crystal structures (27, 28) provide evidence that antibody resis-
tance is complex, with mutations distant from the targeted
epitope affecting antibody binding, presumably through struc-
tural changes (26). Therefore, further studies of the antibody re-
sponse to a varied range of envelope proteins in vivo are required.
As animal models of HCV infection and adaptive immunity are
suboptimal, we can still gain useful information from studying the
humoral responses of chronically infected individuals using in
vitromodels.
Although there is evidence that bNAbs have clinical relevance
in acute infection, their role in chronic infection is not clear. In-
deed, the immune response to HCV can have pathological conse-
quences, as seen in cryoglobulinemic vasculitis (29). If large-scale
vaccination were to be considered, it would be important to de-
termine that stimulation of a bNAb response would not be harm-
ful in the event of an authentic infection. Studying the clinical
associations in patients with bNAbs can reveal potential adverse
outcomes and yield insights into factors associated with neutral-
izing antibody (NAb) production.
In this study, we investigated the bNAb responses in patients
chronically infected with HCV (CHCV patients), determined
whether any association exists between the bNAb response and
clinical and host factors, and characterized the epitopes targeted
by these antibodies. We identified an association between the
bNAb response and less severe liver disease and show that a bNAb
response targetsmultiple neutralizing E2 epitopeswithin different
immunodomains. We also report an association between the
bNAb response and age; however, no association between the
bNAb response and the estimated duration of infection or age at
the time of infectionwas found. Finally, we confirm that the single
nucleotide polymorphism (SNP) rs2395522 in theHLA-DQ gene
is strongly associated with the production of a bNAb response.
MATERIALS AND METHODS
Patient characteristics. CHCV subjects infected with either gt1 or gt3
HCV were prospectively recruited from three local liver clinics. Individ-
uals with coexisting liver pathologies, a bodymass index (BMI) of31, or
hepatocellular carcinoma were excluded. Healthy controls with no liver
pathologies or significant comorbidities were also recruited, and samples
from those subjects were used as negative controls in subsequent experi-
ments. All subjects completed a symptom questionnaire, clinical details
were recorded, and baseline biochemistry, virology, and interleukin-28B
(rs12979860) profiles were determined. Liver stiffness was measured by
transient elastography using a FibroScan instrument (Echosens). Serum
and whole-blood samples were obtained and stored at 70°C. Ethical
approval for this study was granted by the West of Scotland Research
Ethics Committee, and all patients gave informed consent.
Cell lines. Human hepatoma Huh7 cells, Huh7-J20 cells (30), and
human epithelial kidney 293T (HEK293T) cells were grown inDulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum, 5%
nonessential amino acids, penicillin, streptomycin, and 200 mM L-glu-
tamine. Huh7-J20 cells were supplemented with 2 g/ml puromycin.
Antibodies. The anti-E2 human monoclonal antibodies (HMAbs)
CBH-4B, CBH-7, HC-1, HC-11, and HC-84 (31–33) were a generous gift
from Steven Foung. The anti-E2 mouse MAb AP33 has been described
previously (34).
E1E2 binding assay. The enzyme-linked immunosorbent assay
(ELISA) used to detect antibody binding to HCV glycoproteins was per-
formed as described previously (35). Briefly, HCV glycoproteins in lysates
of HEK293T cells transfected with E1E2 expression plasmids were cap-
tured ontoGalanthus nivalis agglutinin (GNA)-coated Immulon II plates
(Thermo Labsystems). Protein G-purified patient IgG was isolated from
serum using an NAb protein G spin kit (Thermo scientific), and the con-
centration was quantified by determination of the absorbance at 280 nm.
Purified patient IgGwas added at 200g/ml in phosphate-buffered saline
(PBS) containing 0.05% Tween 20 and 2% skimmed milk powder
(PBSTM), and bound antibodies were detected using horseradish perox-
idase (HRP)-conjugated anti-human IgG antibody (catalog number
A0170; Sigma) and 3,3,5,5=-tetramethylbenzidine (TMB; Sigma) sub-
strate. Two representative samples from healthy control subjects were
included for quality control purposes. Serial dilutions of MAb AP33,
which binds to a highly conserved linear epitope, were included to gener-
TABLE 1 Demographic characteristics of cohortsa
Demographic characteristicb Result
Median (range) age (yr) 46 (28–68)
No. (%) of male subjects 35 (68.6)
No. (%) of Caucasian subjects 47 (92.2)
No. (%) of subjects with IVDU as a source
of infection
32 (62.7)
Median (range) estimated duration of
infection (yr)
25 (2–58)
No. (%) of subjects with IL-28B CC
genotype (rs12979860)
17 (35.4)c
No. (%) of subjects anti-HBc positive 11 (24.4)d
Mean (range) BMI (kg/m2) 26 (19–31.5)
No. (%) of subjects with diabetes 2 (3.92)
No. (%) of subjects previously exposed to
interferon-based treatmente
21 (46.7)d
Median (range) HCV RNA load
pretreatment (IU/ml)
6.8 105 (2,272–1.1 107)
No. (%) of subjects with cirrhosis 18 (36)
Median (range) transient elastography
reading (kPa)
9 (4–75)
a The data are for 51 subjects with CHCV infection.
b IVDU, intravenous drug use; IL-28B, interleukin-28B.
c Three subjects were not tested.
d No information was available for 6 subjects.
e All individuals had HCV infection at the time of testing; those previously exposed to
interferon were either relapsers or null responders. No individuals were on therapy at
the time of sampling.
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FIG 1 Molecular phylogenetic analysis ofHCVgt1 E1E2 amino acid sequences by themaximum likelihoodmethod using the JTTmatrix-basedmodel (55). A discrete
gamma distribution was used to model differences in the evolutionary rates among sites (5 categories [gamma distribution parameter 0.3680]). The tree with the
highest log likelihood (7,055.2655) is shown. The tree is drawn to scale, and the genetic distance for each branch length is indicated by the scale bar. Bootstrap analysis
with 1,000 replicates was performed. The percent support for branches with70% bootstrap support is indicated. Blue, sequences classified to be functional in the
HCVpp system; red, nonfunctional sequences; green, sequences included in the gt1 panel. Evolutionary analyses were conducted with theMEGA (v.6) program (56).
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ate a standard curve on each plate. This allowed the absorbance value from
antibody binding to E1E2 by each test sample to be expressed as an equiv-
alent concentration of AP33 (g/ml), which enabled comparison across
plates.
Generation of HCVpp and HCVcc and neutralization assays.
HEK293T cells were cotransfected with plasmids expressing murine
Moloney leukemia virus (MLV) gag-pol, an MLV transfer vector carrying
a firefly luciferase reporter, and a plasmid expressing the relevant HCV
E1E2. After 72 h, the medium was harvested, filtered through a 0.45-m-
pore-size membrane, and used as a source of HCV pseudoparticles
(HCVpp) as described previously (36). Infectious virus was produced in
Huh7 cells by electroporation of RNA encoding full-length JFH-1 or chi-
TABLE 2 ELISA binding of antibodies from the CHCV patient cohort to cross-genotypic E1E2 panel
Patient IgG
Equivalent concn (g/ml) of AP33a
Overall rankgt1a gt1b gt2a gt2b gt3a gt4
C1001 6.75 (19) 33.07 (2) 1.44 (11) 2.32 (8) 7.73 (19) 5.92 (19) 6
C1002 0.39 (50) 0.40 (51) 0.06 (51) 0.02 (51) 3.63 (33) 0.05 (48) 50
C1003 13.36 (12) 18.70 (9) 2.77 (6) 0.60 (15) 61.91 (1) 67.63 (2) 1
C1006 4.92 (24) 6.02 (31) 0.34 (31) 0.12 (29) 4.90 (29) 1.84 (37) 34
C1008 1.53 (39) 10.75 (21) 0.38 (27) 0.16 (21) 57.21 (2) 0.64 (46) 28
C1009 1.46 (41) 7.36 (27) 0.39 (25) 0.10 (36) 27.32 (4) 0.57 (47) 33
C1010 86.76 (1) 5.17 (34) 0.42 (22) 0.14 (25) 2.15 (41) 4.16 (24) 27
C1012 31.43 (7) 13.80 (15) 0.55 (17) 0.44 (17) 23.09 (6) 50.27 (3) 4
C1013 3.57 (28) 6.01 (32) 0.20 (45) 0.15 (49) 3.24 (35) 2.70 (34) 42
C1015 0.94 (46) 9.19 (25) 0.43 (21) 0.15 (23) 34.57 (3) 4.02 (27) 26
C1016 7.94 (17) 13.10 (19) 0.65 (15) 0.23 (18) 19.64 (9) 17.69 (7) 9
C1018 8.25 (16) 14.50 (13) 0.37 (28) 0.19 (19) 7.11 (22) 6.57 (17) 15
C1020 2.38 (33) 3.01 (43) 0.33 (33) 0.10 (35) 22.09 (8) 0.72 (45) 36
C1021 26.58 (8) 13.18 (18) 1.23 (12) 3.05 (5) 3.43 (34) 27.45 (4) 7
C1022 39.09 (4) 4.54 (37) 0.26 (40) 0.08 (39) 2.41 (40) 9.83 (11) 29
C1023 14.28 (10) 13.46 (16) 0.15 (49) 0.12 (28) 16.76 (10) 11.21 (9) 19
C1024 2.97 (29) 2.87 (45) 0.33 (32) 0.11 (32) 3.84 (31) 1.15 (41) 40
C1029 6.45 (21) 12.76 (20) 0.43 (20) 0.10 (37) 22.74 (7) 9.31 (13) 18
C1030 6.65 (20) 4.86 (35) 0.34 (29) 0.11 (31) 0.78 (49) 1.60 (38) 38
C1031 34.53 (5) 7.04 (29) 0.77 (14) 0.13 (27) 2.53 (38) 10.70 (10) 20
C1032 8.39 (15) 10.08 (23) 0.43 (19) 0.09 (38) 6.05 (26) 22.85 (5) 21
C1033 0.69 (47) 3.67 (40) 0.21 (44) 0.06 (47) 2.43 (39) 0.05 (49) 49
C1034 6.38 (22) 13.44 (17) 0.38 (26) 0.13 (26) 25.72 (5) 18.91 (6) 11
C1035 76.17 (2) 8.20 (26) 0.30 (35) 0.12 (30) 2.06 (42) 13.33 (8) 24
C1036 1.72 (36) 20.77 (6) 1.53 (9) 2.26 (9) 3.77 (32) 5.57 (20) 14
C1037 2.71 (31) 7.14 (28) 0.13 (50) 0.16 (22) 1.50 (44) 3.57 (28) 39
C1038 1.87 (35) 9.74 (24) 0.26 (39) 0.00 (44) 1.34 (47) 2.85 (33) 41
C1040 12.29 (14) 27.97 (3) 4.51 (3) 4.33 (4) 2.96 (36) 9.78 (12) 5
C1041 0.98 (45) 5.48 (33) 0.21 (43) 0.06 (46) 8.51 (16) 0.80 (44) 43
C1042 41.33 (3) 6.02 (30) 0.34 (30) 0.19 (20) 7.42 (20) 9.10 (14) 17
C1043 1.08 (44) 20.65 (7) 1.88 (7) 2.98 (6) 7.08 (23) 4.52 (23) 12
C1045 1.56 (38) 3.30 (42) 0.26 (37) 0.04 (45) 0.34 (50) 1.50 (39) 47
C1046 14.0 (11) 23.83 (5) 1.50 (10) 1.69 (12) 5.65 (27) 6.88 (16) 7
C1047 32.15 (6) 3.53 (41) 0.26 (38) 0.10 (34) 1.46 (45) 1.95 (36) 37
C1049 2.69 (32) 1.54 (49) 0.28 (36) 0.14 (24) 10.31 (13) 2.93 (32) 35
C1050 18.84 (9) 4.29 (38) 0.24 (41) 0.10 (33) 10.53 (12) 95.25 (1) 23
C1052 0.68 (48) 1.65 (48) 0.17 (48) 0.10 (48) 7.23 (21) 0.84 (50) 48
C1054 5.78 (23) 2.90 (44) 0.32 (34) 0.06 (40) 15.58 (11) 4.59 (22) 30
C1055 2.72 (30) 2.56 (46) 0.23 (42) 0.06 (41) 2.85 (37) 1.03 (42) 46
C1056 3.89 (27) 2.20 (47) 0.20 (46) 0.02 (43) 4.84 (30) 1.36 (40) 45
C1057 1.11 (43) 1.51 (50) 4.00 (4) 16.45 (1) 1.36 (35) 2.54 (35) 32
C1060 1.49 (40) 4.79 (36) 21.84 (1) 7.94 (51) 0.21 (51) 5.13 (51) 44
C1061 6.96 (18) 34.01 (1) 3.93 (5) 6.43 (2) 9.87 (14) 8.07 (15) 2
C1062 4.68 (26) 19.17 (8) 1.85 (8) 2.46 (7) 9.06 (15) 3.05 (31) 10
C1063 0.55 (49) 13.81 (14) 0.58 (16) 1.06 (13) 6.26 (25) 4.06 (26) 24
C1064 0.14 (51) 4.19 (39) 0.19 (47) 0.68 (50) 1.23 (48) 0.97 (43) 51
C1072 1.16 (42) 10.15 (22) 0.39 (24) 0.71 (14) 1.98 (43) 3.19 (29) 30
C1074 1.63 (37) 16.45 (10) 0.91 (13) 2.00 (11) 7.91 (18) 5.51 (21) 12
C1089 2.02 (34) 16.16 (12) 0.44 (18) 2.14 (10) 8.01 (17) 4.14 (25) 16
C1112 13.35 (13) 25.42 (4) 5.25 (2) 5.53 (3) 6.29 (24) 6.00 (18) 3
C1128 4.76 (25) 16.26 (11) 0.40 (23) 0.55 (16) 5.56 (28) 3.12 (30) 22
a The equivalent concentration of AP33 determined from the A450 of each sample. The E1E2 binding rank from the strongest (with a rank of 1) to the weakest (with a rank of 51) is
shown in parentheses.
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meric JFH-1. The intragenotypic chimera 2B.1.1/JFH1 and the intergeno-
typic chimera gt1a H77/JFH1 (HQL) have been described previously (20,
30). For neutralization assays, HCVpp and purified patient IgG at 100
g/ml (equivalent to a serum dilution of 1:100 to 1:250 on the basis of the
known IgG levels in sera from patients with chronic HCV [37]) were
mixed, and the mixture was incubated for 1 h at 37°C and then used to
infect Huh7 cells for 4 h. The inoculum was removed, and fresh medium
was added. Cells were lysed at 3 days postinfection, and infectivity was
assessed using a GloLysis luciferase assay (Promega). Similarly, the neu-
tralization of cell culture infectious HCV (HCVcc) infection was tested in
Huh7-J20 cells, and infectivity was assessed at 3 days postinfection using a
Phospha-Light assay system (Thermo Fisher) to measure secretory alka-
line phosphatase (SEAP) levels (30).
Amplification of viral E1E2 sequences derived from patients. A
cDNA library was created from HCV RNA isolated from patient serum
using a QIAamp viral RNAminikit (Qiagen). The complete E1E2-encod-
ing regionwas amplified using degenerate nested primers (Gt1 outer sense
primer 5=-GTGAAYTAYGCRACAGGGAA, Gt1 outer antisense primer
5=-GCAAAGCAGAARAACACGAG, Gt1 inner sense primer 5=-CACCA
TGGGTTGCTCYTTYTCTATCTTC, Gt1 inner antisense primer 5=-AAA
GTTTCTAGATTACYGCCTCYGCYTGGGAKA) and cloned into the
phCMVexpression vector using aGateway recombination cloning system
(Invitrogen).
DNA isolation and SNP analysis. DNA was extracted from whole
blood using the QIAamp DNA minikit (Qiagen). Custom primers for
SNP rs2395522 and a reporter dye mix (Thermo Fisher) were included in
the quantitative PCRmixtures, and PCR was performed with Taqmaster
mix on a 7500HT Fast real-time PCR system (Applied Biosystems). Sam-
ples were assigned to be A/T heterozygotes or AA or TT homozygotes
according to the fluorescence signal.
Epitope targeting. A soluble form of the gt1a E2 (H77) protein (sE2)
was purified following expression in High Five insect cells. Immulon II
plates were coatedwith sE2 at 1g/ml and incubatedwith purified patient
IgG at 200 g/ml in PBSTM. Subsequently, biotinylated antibodies to
known epitopes were added at a concentration close to their half-maximal
(50%) effective concentration (EC50) (14, 17, 18, 38). Streptavidin-HRP
was added, and binding was measured as described above. The reduction
in the relative binding of each biotinylated antibody (calculated as the
percent reduction in the absorbance) on addition of patient IgG com-
pared to that for the PBSTM control was determined.
Analysis. Analysis of the results of the assays and any statistical anal-
ysis of an association with clinical features were conducted using Graph-
Pad Prism (v.6) software (GraphPad Software, La Jolla, CA) and SPSS (v.
19.09) software (IBM,NY). Statistical comparisonsweremade using non-
parametric tests (the chi-square test for categorical data, the Wilcoxon
rank-sum test for ordinal or numeric data), unless otherwise stated.
Nucleotide sequence accession numbers. The novel HCV E1E2 se-
quences reported here have been deposited in GenBank under accession
numbers KU645403 to KU645407.
RESULTS
Cohort. Fifty-oneHCV-infected patients (27 infected with gt1, 24
infected with gt3) from the CHCV patient cohort and 8 healthy
controls were recruited. The demographic characteristics of the
cohort are shown in Table 1. Apart from a higher prevalence of
individuals with an Asian ethnicity in the gt3-infected group
(P  0.04), there were no significant differences in the demo-
graphic characteristics between subjects infected with either
gt1 or gt3 HCV.
E1E2HCVpp panels. To determine the reactivity and neutral-
ization activity of patient-derived IgG across a diverse range of
envelope sequences, two panels of HCV pseudoparticles bearing
test envelope proteins were used. The first, termed panel XG, en-
abled analysis of antibody reactivity with E1E2 proteins of differ-
ent viral genotypes. This panel comprised E1E2 from 6 subgeno-
types (39): gt1a H77c (GenBank accession number AF011751),
gt1b UKN1B5.23 (GenBank accession number AY734976),
gt2a JFH-1 (GenBank accession number AB047639), gt2b
UKN2B1.1 (GenBank accession number AY734982), gt3a
UKN3A13.6 (GenBank accession number AY894683), and
gt4 UKN4.11.1 (GenBank accession number AY734986). The
second, termedpanelGt1, was created to allow the investigation of
antibody reactivity with E1E2 proteins of a single genotype, like
that which might arise during a natural infection. One hundred
three patient-derived E1E2 sequences collected from 18 gt1HCV-
infected patients in three cohorts across the United Kingdom (the
Trent HCV study group [40], the St. Mary’s acute hepatitis C
cohort 41], and the Glasgow chronic HCV cohort [42]) were
tested for infectivity in the HCVpp system (data not shown). As
previously found in other studies, not all sequences were infec-
tious in this system (25, 43). Sixty-four percent of the E1E2 se-
FIG 2 Association of viral load with E1E2 binding and neutralization profiles.
(A) The relative binding of CHCVpatient cohort IgG to E1E2 from6 subgeno-
types of HCV was determined by ELISA. The IgG samples were ranked from 1
to 51 according to their binding signal for each subgenotype. The sum of these
ranks was used to order the samples from those with the highest cross-geno-
typic binding to those with the lowest. The binding of antibodies from the
upper half of the cohort was considered broad, and that of antibodies from the
lower half was considered narrow. The viral loads of the two groups were
compared using the Mann-Whitney U test. (B) The neutralization of HCVpp
in both panels by purified IgG was determined at the 50% level. The neutral-
ization of HCVpp in panel XG by IgG antibodies from all individuals in the
CHCV patient cohort and the neutralization of HCVpp in panel Gt1 by IgG
antibodies from 20 gt1-infected individuals were tested. The Mann-Whitney
U test was used to compare the viral load between broad neutralizers,
which were those that neutralized3 HCVpp (n 19) in panel XG and7
gt1 HCVpp (n  10) in panel Gt1, and narrow neutralizers, which were
those that neutralized 4 genotypes (n  32) in panel XG and 8 gt1
HCVpp (n  10) in panel Gt1.
Swann et al.
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TABLE 3 Neutralization activity of antibodies form the CHCV patient cohort
Patient IgG
HCVpp HCVcc
Final overall
rank
Relative neutralization activity (%)a
Rank for
HCVpp
Relative neutralization
activity (%)a
Rank for
HCVccgt1a gt1b gt2a gt2b gt3a gt4 gt1a gt2a gt2b
C1001 70.1 45.1 45.8 5.1 47.8 67.3 32 32.5 28.7 17.6 35 34
C1002 13.7 6.8 20.9 4.2 34.2 15.9 51 9.8 6.6 14.7 50 51
C1003 83.8 61.9 84.4 30.2 66.3 89.6 2 54.7 51.7 13.8 7 2
C1006 61.2 16.1 54.0 18.3 36.2 77.4 36 26.5 16.8 14.3 47 46
C1008 54.6 42.5 65.0 23.7 77.5 73.5 20 29.9 21.4 1.2 51 36
C1009 50.8 39.3 67.3 20.9 48.4 71.4 28 24.5 28.6 6.3 49 41
C1010 72.9 51.3 73.1 37.0 45.7 86.1 8 36.5 20.9 20.3 31 18
C1012 77.7 51.5 84.9 45.4 76.2 86.7 1 44.0 40.0 20.9 8 2
C1013 85.8 43.3 39.4 30.8 48.9 70.0 25 51.6 24.4 31.1 13 17
C1015 68.0 37.3 66.7 26.8 48.7 82.9 15 37.9 47.5 15.1 17 12
C1016 79.9 61.3 88.9 7.4 74.9 89.1 5 42.1 46.0 32.6 6 4
C1018 76.8 50.8 40.4 6.2 49.6 79.6 23 31.3 37.7 23.4 27 26
C1020 56.1 44.7 38.8 5.0 53.0 83.3 31 26.6 37.2 34.0 24 29
C1021 62.7 34.7 55.4 25.7 46.2 88.1 22 44.5 64.2 56.9 1 8
C1022 66.9 49.6 63.3 32.5 51.6 81.3 12 35.6 40.5 31.3 13 10
C1023 62.8 49.3 67.1 6.8 73.5 90.1 13 38.6 37.3 9.3 28 20
C1024 55.4 65.6 72.5 29.0 40.2 76.8 17 35.2 42.1 30.3 16 13
C1029 46.4 30.9 83.2 13.4 67.1 87.8 18 40.9 36.1 11.9 25 22
C1030 47.2 33.3 54.9 26.4 27.9 79.6 38 24.5 36.6 8.0 44 44
C1031 51.7 37.4 11.0 38.2 31.6 75.3 41 40.1 19.3 43.2 22 31
C1032 72.6 44.8 81.0 40.3 79.1 86.0 11 41.8 54.2 41.4 5 6
C1033 23.5 68.3 34.4 13.7 27.8 61.9 44 25.7 28.6 26.5 37 43
C1034 47.3 33.7 47.3 16.6 26.4 59.1 42 30.8 27.1 15.2 40 44
C1035 80.7 56.0 66.7 45.1 48.3 87.5 5 35.1 25.5 1.9 45 26
C1036 67.2 47.7 52.2 23.7 22.5 65.1 35 36.0 17.0 30.8 29 32
C1037 84.3 54.8 65.5 16.1 61.6 90.9 9 34.0 19.7 26.9 33 21
C1038 38.6 40.6 77.1 29.4 51.7 79.0 21 38.7 53.4 12.5 25 24
C1040 75.3 53.4 34.4 29.6 29.4 63.6 32 30.8 39.8 3.5 39 36
C1041 66.6 29.2 43.7 25.8 71.5 71.9 27 33.3 39.9 1.5 37 32
C1042 67.9 57.0 57.4 39.6 80.2 89.9 4 67.0 65.2 21.8 2 1
C1043 44.4 45.5 31.7 4.1 32.9 60.7 48 48.6 35.0 19.9 31 42
C1045 64.5 36.3 37.2 36.3 22.6 65.0 39 51.5 47.5 10.7 18 30
C1046 79.4 60.0 62.5 50.2 64.0 82.9 3 39.9 61.8 3.5 20 8
C1047 78.2 42.2 40.3 45.6 62.9 71.4 26 46.3 57.0 5.9 10 15
C1049 58.1 24.0 66.8 45.0 50.3 82.0 14 42.0 48.8 12.8 12 11
C1050 84.4 49.5 51.5 45.5 54.3 76.2 9 59.6 60.3 21.8 4 5
C1052 62.0 29.6 34.5 14.3 19.7 54.2 49 34.5 35.8 5.6 42 49
C1054 13.6 5.0 39.1 5.5 37.1 82.7 46 41.6 38.8 10.1 23 35
C1055 61.5 0.2 32.1 1.7 53.7 79.2 37 33.8 43.0 3.6 35 38
C1056 73.8 0.3 53.1 21.4 50.1 73.3 28 45.4 54.2 9.6 9 16
C1057 41.3 49.1 60.4 29.4 56.8 70.0 24 36.4 44.4 14.5 21 23
C1060 67.0 38.2 49.7 31.2 45.9 65.8 34 43.1 39.6 11.7 18 28
C1061 65.2 55.5 46.0 31.9 52.8 75.8 16 52.1 50.5 38.5 3 7
C1062 46.3 60.5 10.2 0.3 41.2 60.2 45 39.4 21.4 14.6 30 40
C1063 27.8 32.4 39.1 15.2 43.5 72.2 42 22.1 38.1 11.7 48 48
C1064 24.6 37.9 31.8 12.6 34.1 48.2 50 16.6 30.8 10.9 46 50
C1072 72.5 47.2 39.2 21.8 28.8 60.2 40 37.2 34.1 11.3 33 39
C1074 61.3 37.4 41.0 34.1 37.2 76.0 28 42.5 38.0 24.1 11 18
C1089 28.4 23.9 23.6 26.4 44.9 60.5 47 38.4 30.9 6.6 41 47
C1112 71.1 48.1 63.5 38.9 50.3 69.8 19 50.0 36.4 17.5 15 14
C1128 81.7 70.3 48.1 39.0 65.9 81.9 7 32.6 39.2 33.7 42 25
a Values for the neutralization of HCVpp of 50% and neutralization of HCVcc of 40% are shown in bold, and values for the neutralization of HCVpp of 20% are
indicted with underlining. The rank of neutralization of HCVpp and HCVcc within the cohort from the strongest (with a rank of 1) to the weakest (with a rank of 51) is
shown in bold and italics.
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quences tested were functional, giving a robust luciferase signal
10-fold above the background. All the amino acid sequences
were aligned by use of the ClustalW program, and the best protein
model with the lowest Bayesian information criterion score
(16,423.799) was used to generate a phylogenetic tree using the
maximum likelihood method (Fig. 1). The panel selection crite-
rion was based on the overall genetic difference (p distance) and
the representation of the amino acid variability found in all gt1
E1E2 sequences registered with the Los Alamos HCV sequence
database. Analysis of 3,800 gt1 E1E2 sequences in the database
identified 400 amino acid (aa) residues that were conserved in at
least 90% of sequences; of these, the majority (306 aa) were con-
served in 99% of sequences. One hundred fifty-four amino acids
were found to be variable in more than 10% of the gt1 E1E2 se-
quences. Eleven infectious sequences, including the reference gt1a
sequence H77 and 10 patient-derived E1E2 sequences from 9
HCV-infected individuals were selected for inclusion in the gt1
panel (GenBank accession numbers AF011751, AY734976,
AY734971.1, AY734968.1, EU155192.1, and KU645403 to
KU645407). These sequences represent the variability at 145/154
variable residues. In addition, 31 aa residues representminor vari-
ants found in less than 10% of the sequences in the database.
Cross-genotypic antibody reactivity is associated with a
lower viral load. Patient IgG reactivity to whole E1E2 from panel
XG was tested by ELISA. The relative binding strength based on
the absorbance readings normalized to those on anAP33 standard
curve were ranked from 1 (the highest) to 51 (the lowest) for each
genotype; the ranks for all genotypes were combined, and a final
rank position was assigned (Table 2). This gave an overall indica-
tion of the relative antibody binding breadth for each patient. The
cohort was divided in half by breadth-of-binding rank, and the
individuals in the top half of the breadth-of-binding rank were
compared to those in the lower half to determine whether any
clinical associations with breadth of antibody binding existed.
Those with broader ELISA reactivity profiles had a significantly
lower viral load (P  0.03; Fig. 2A). Individuals for which the
breadth of binding was broader were more often infected with gt1
HCV, and, conversely, individuals for which the breadth of bind-
ing was narrower were more often infected with gt3 HCV (P 
0.04 for both comparisons; data not shown). These associations
appear to be independent, as there was no association between the
genotype of the infecting virus and the viral load (P 0.59) (data
not shown).
Neutralization is not associatedwith viral load.Purified IgGs
derived from theCHCVpatient cohort were tested for their ability
to neutralize HCVpp bearing envelope proteins from panel XG
and HCVcc bearing envelope proteins from gt1a (1A-HQL), gt2a
JFH-1, and gt2B.1.1 (Table 3). In accordance with the findings of
Urbanowicz and coworkers, we found that HCVpp were more
readily neutralized than HCVcc (25). Therefore, neutralization
was categorized as a reduction in infectivity of 50% in the HCVpp
system and 40% in the HCVcc system. In both systems, gt2B.1.1
was particularly resistant to neutralization. The breadth of neutral-
ization of HCVpp in panel XG, defined as broad (neutralization of
3/6 genotypes) or narrow (neutralization of4/6 genotypes), was
analyzed for anassociationwith clinical factors.Twenty (40%)of the
51 individuals tested had broad cross-genotypic neutralizing IgGs.
There were no significant associations between the breadth of
cross-genotypic neutralization and the viral load (Fig. 2B). Simi-
larly, IgGs from 20 CHCV individuals with gt1 infection were
tested for neutralizing activity against HCVpp in panel Gt1 (Table
4), and the number of pseudoparticles neutralized to the 50% level
by each individual was calculated. The neutralization of 7/11
strains was defined to be broad, while the neutralization of8/11
strains was defined to be narrow. As with panel XG, there was no
TABLE 4 gt1-specific neutralization of HCVpp in panel Gt1
Patient IgG
Relative neutralization (%) of HCVpp in panel Gt1a
No. of
samples with
50%
neutralizationgt1a H77 UKN1B5.23 UKN1A14.38 UKN1A14.43 UKN1B14.818 UKN1A20.8 GC12.02 GC13.01 GC34.11 GC37.04 ET10
C1001 70.1 45.1 72.0 60.6 80.5 10.6 29.3 44.6 52.4 53.4 72.9 7
C1002 13.7 6.8 13.1 22.0 0.11 8.8 17.1 24.1 7.6 1.6 13.1 0
C1003 83.8 61.9 54.4 64.1 88.6 25.4 57.2 54.5 53.1 84.5 90.2 10
C1010 72.9 51.3 46.1 55.8 87.0 17.7 43.7 41.4 54.8 76.6 69.5 7
C1012 77.7 51.5 75.7 57.9 87.1 23.7 53.6 49.5 66.6 84.4 78.7 9
C1013 85.8 43.3 66.6 72.2 80.9 37.2 61.2 58.3 89.0 80.6 88.0 9
C1016 79.9 61.3 66.2 49.3 94.0 44.0 50.2 40.5 63.5 75.3 88.7 8
C1022 66.9 49.6 48.9 46.4 64.7 24.1 54.7 53.1 55.1 65.7 75.6 7
C1023 62.8 49.3 56.1 68.5 72.1 17.2 73.5 64.8 75.9 70.9 76.8 9
C1030 47.2 33.3 27.3 20.1 62.9 16.5 23.1 20.4 21.3 47.9 59.6 2
C1031 51.7 37.4 55.7 55.5 70.1 27.6 46.2 64.3 72.3 72.2 67.8 8
C1032 72.6 44.8 80.6 81.7 89.7 27.6 57.2 69.5 89.2 73.7 74.4 9
C1034 47.3 33.7 24.0 24.5 50.3 18.1 31.9 3.9 21.6 53.4 41.7 2
C1035 80.7 56.0 61.0 61.9 76.0 44.7 66.6 64.6 70.9 67.2 82.5 10
C1036 67.2 47.7 41.6 50.0 57.5 28.3 50.7 43.8 55.4 69.1 69.5 7
C1037 84.3 54.8 53.7 34.3 76.8 16.2 44.6 41.5 79.2 62.1 75.0 7
C1045 64.5 36.3 29.1 28.2 69.6 0.2 33.1 29.6 52.8 47.9 49.5 3
C1047 78.2 42.2 56.0 57.8 83.3 3.6 51.5 35.4 50.7 62.8 76.8 8
C1072 72.5 47.2 39.5 44.3 61.3 22.8 42.0 25.6 68.2 59.1 65.7 5
C1112 71.1 48.1 52.4 71.3 73.2 25.7 71.3 56.7 78.7 75.0 81.6 9
a Values for the neutralization of HCVpp of50% are shown in bold, and values for the neutralization of HCVpp of20% are indicated with underlining.
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association between the breadth of neutralization of HCVpp in
panel Gt1 and the viral load (Fig. 2B).
Correlation between ELISA binding profiles and neutraliza-
tion. To determine the level of agreement between the ELISA
binding profiles and neutralization activity used to determine an-
tibody breadth, we calculated nonparametric correlation coeffi-
cients between the assays. For the full cohort, there was a modest
correlation between the cross-genotypic ELISA binding rank and
the number of genotypes in panel XG and panel Gt1 neutralized
(Spearman’s rho correlation coefficient0.31 and P 0.03 for
panel XGand Spearman’s rho correlation coefficient0.49 and
P  0.03 for panel Gt1) (Fig. 3A and B). The neutralization of
HCVpp and HCVcc was determined for the full cohort (Table 3).
Overall, there was a significant correlation between the neutraliza-
tion rank in both systems (Spearman’s rho correlation coeffi-
cient 0.44, P 0.001; Fig. 3C). Indeed, the strongest neutraliz-
ing IgGs efficiently neutralizedHCVpp andHCVcc. Interestingly,
IgGs isolated from some individuals neutralized HCVcc more ef-
fectively thanHCVpp and vice versa (compare the results for IgGs
C1021 and C1061 with those for IgGs C1046 and C1035; Table 3).
There was also a significant correlation between the proportion of
genotypes neutralized in the two HCVpp panels (Spearman’s rho
correlation coefficient  0.58, P  0.007; Fig. 3D) for the gt1-
infected subgroup.Neutralization is only one possiblemechanism
through which HCV-binding antibodies exert potential antiviral
selection. The modest correlation between ELISA binding and
neutralization highlights the fact that while an individual with
strong HCV-binding antibodies often has strong neutralizing an-
tibodies, this is not always the case. This disparity is evident in the
lack of an association between the breadth of neutralizing anti-
bodies and the viral load, despite an association between HCV
binding and viral load.
Association of increased age and liver fibrosis with narrow
intragenotype neutralization. The neutralization breadth for
panel XGwas not associatedwith any clinical features (Fig. 4A and
C and 5A, C, and E). Interestingly, analysis of the IgGs from a
subgroup of gt1-infected individuals for their neutralizing activi-
ties against panel Gt1 found an association between the breadth of
neutralization and age, since the group with broadly neutralizing
IgGs was significantly younger (P  0.009; Fig. 5B). However,
there was no association of neutralization breadth with the esti-
mated duration of infection or age of acquisition for the gt1-in-
fected subgroup (Fig. 5D and F). Most notably, there was a strik-
ing association between the breadth of neutralization activity and
liver fibrosis for the gt1-infected subgroup. The group with
broadly neutralizing antibodies had significantly lower levels of
liver fibrosis, as determined by transient elastography (P 0.006;
Fig. 4B), and fewer cirrhotic individuals (P 0.02; Fig. 4D). Im-
portantly, the association between neutralization breadth and Fi-
broScan readings remained significant when corrected for age
(P 0.025, generalized linear model, SPSS, v.19.0).
Role of HLA-DQ polymorphisms in predicting antibody
neutralization breadth.A recent study showed a link between the
breadth of activity of neutralizing antibodies against acute gt1
FIG 3 Nonparametric correlation between E1E2 ELISA binding and neutralization. (A, B) The number of HCVpp neutralized was plotted against the ELISA
binding rank for panel XG (A) and panel Gt1 (B). (C) The neutralization activity of antibodies from the full cohort against HCVpp in panel XG and the HCVcc
viruses (1A-HQL, JFH-1, 2B1.1/JFH1) was analyzed, and the neutralization rank in the HCVcc and HCVpp systems was plotted. (D) For those gt1-infected
individuals whose antibodies were tested for reactivity against HCVpp in both panels, the number of HCVpp isolates in panel XG neutralized was plotted against
the number of HCVpp isolates in panel Gt1 neutralized. Spearman’s rho correlation coefficient was calculated for all graphs.
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HCV infection and an SNP (designated rs2395522) in a major
histocompatibility complex class II gene,HLA-DQB1, involved in
antigen presentation (12). Therefore, we analyzed our cohort for
any association between the presence of different alleles at this
SNP and the number of HCVpp neutralized in both panels. There
was no significant association between the different alleles of this
gene and the number of HCVpp neutralized in panel XG (P 
0.41; Fig. 6A). However, the presence of the rs2395522 AA or AT
allele was significantly associated with a greater number of
HCVpp in panel Gt1 neutralized (P 0.038; Fig. 6C). There was
no association between SNP rs2395522 and liver fibrosis for either
panel (P 0.2 and P 0.62; Fig. 6B andD). In addition, we tested
another genetically linked HLA-DQA2 SNP, rs9275224. Here the
GG or AG allele was also significantly associated with an increased
breadth of neutralization of HCVpp in panel Gt1 (P 0.038; data
not shown, as the graphs are identical due to the genetic linkage
between the SNPs). SNP rs2395522 is present in the intergenic
region ofHLA-DQB1; the functional consequences are unknown.
However, the linked SNP rs9275224 is associated with autoim-
mune diseases, including systemic sclerosis and rheumatoid ar-
thritis (44, 45).
E2 epitopes targetedbypatient IgG. In an effort to understand
the epitopes targeted by the gt1-infected patient IgGs used for the
intragenotypic analysis, we determined if they competed for bind-
ing to E2with somewell-characterized antibodies. The conforma-
tional antibodies selected have been characterized to bind to
specific hypothetical immunodomains of E2, designated immu-
nodomains A, B, and C. Their precise locations on E2 have not
been identified to date; however, antibodies that bind to immu-
nodomainA, includingHMAbCBH-4B, are nonneutralizing. An-
tibodies that bind to immunodomain B (HMAbs HC-1, HC-11,
and HC-84) and immunodomain C (HMAb CBH-7) are able to
neutralize HCV. While immunodomain C has not been charac-
terized, immunodomain B has been shown to contain the CD81
receptor binding site (15). Lastly, the mouse NAb AP33, which
binds a linear epitope (aa 412 to 423), was also selected. The ma-
jority of the broadly neutralizing samples were able to efficiently
compete with 3 or more of the E2 antibodies tested; in contrast,
most of the narrowly neutralizing samples could compete with
only 2 E2 antibodies or less (Fig. 7A). Interestingly, while 15/20
samples tested competed with HMAb HC-11 at the 50% level,
the majority of broadly neutralizing samples inhibited both
HMAb CBH-7 and HC-11 binding; 6/10 broadly neutralizing
samples recognized different neutralizing immunodomains of E2,
whereas 1/10 narrowly neutralizing samples recognized different
neutralizing immunodomains of E2. There was also a significant
association with intragenotype 1 neutralization breadth (P 
0.004 and P  0.002 for broadly and narrowly neutralizing sam-
ples, respectively; Fig. 7B). Together, these data suggest that indi-
viduals with a broadly neutralizing phenotype have antibodies
that compete with known bNAbs that target multiple sites on E2.
Moreover, they have antibodies that efficiently bind to more than
FIG 4 Association of liver fibrosis with neutralization. The neutralization of HCVpp in panel XG by IgGs from the full CHCV patient cohort (A, C) or HCVpp
in panel Gt1 by IgGs from the gt1-infected subgroup (B, D) was determined as described in the legend to Fig. 2. (A, B) The broadly and narrowly neutralizing
groups were defined as described in the legend to Fig. 2, and transient elastography values, measured using a FibroScan instrument, were compared using the
Mann-Whitney U test. (C, D) The number of HCVpp isolates neutralized by IgG from individuals with and without cirrhosis was compared using the
Mann-Whitney U test.
Swann et al.
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one neutralizing immunodomain, whereas those with a narrow
neutralizing profile effectively target limited numbers of neutral-
izing epitopes.
DISCUSSION
Our analysis of a clinical cohort chronically infectedwithHCVhas
yielded new insights into the importance of the antibody response
in disease progression and factors associated with the functional
breadth of the antibody response. A broad cross-genotype HCV-
binding antibody response was significantly associated with gt1
HCV infection and independently with reduced viral loads. Im-
portantly, these clinical associations with broad HCV binding
were not evident when the breadth of neutralization activity was
analyzed, highlighting distinct biological roles for nonneutralizing
and neutralizing anti-HCV antibodies. The association of ELISA
binding and lower viral loads could reflect the presence of anti-
bodies binding to conserved nonneutralizing regions, which
would help clear the virus from serum through opsonization and
subsequent phagocytosis, as demonstrated by Eren and coworkers
(38), or complement-dependent lysis but would not directly in-
hibit hepatocyte cell entry. Indeed, there is evidence that binding
of virus by nonneutralizing antibodiesmay prevent neutralization
by antibodies targeting the epitopes required for cell entry (46).
While no clinical features were significantly associated with
broad or narrow neutralization, as characterized using panel XG,
we did observe significant associations using a larger intrageno-
type 1 panel. Most importantly, we show that individuals infected
with HCV gt1 who are better able to neutralize an HCVpp panel
incorporating different gt1 E1E2 sequences are less likely to have
cirrhosis or significant liver fibrosis. The panel is composed of
HCVpp from strains that were collected from different geograph-
ical locations in the United Kingdom over the past decade and
incorporates strains with changes at the majority of variable
amino acid positions observed within a large sequence database.
Therefore, the sequences of the strains in this panel represent the
most common viable amino acid substitutions that may occur
within host virus.
The association between lower levels of liver fibrosis and
bNAbs is insufficient evidence alone to demonstrate a protective
effect. However, this adds to the findings of case studies which
have suggested that individualswith genetic or iatrogenic suppres-
sion of the antibody response show a more rapid progression to
liver disease (47, 48). It is biologically plausible that individuals
possessing antibodies capable of preventing the spread of new
variants of their infecting HCV strain may have a degree of pro-
tection from liver injury. Interestingly, this group with a broad
neutralization profile was also significantly younger. This may
suggest that the higher levels of liver fibrosis observed in the group
with a narrow neutralization profile were simply caused by the
longer duration of infection. However, we found no difference in
the duration of infection between the groups with broad and nar-
row neutralization profiles, and, importantly, the association be-
FIG 5 Association of age with breadth of neutralization. We compared the ages of the individuals in the broadly and narrowly neutralizing groups in the full
CHCV cohort tested against panel XG (A) and in the broadly and narrowly neutralizing gt1 subgroups tested against panel Gt1 (B) as characterized in Fig. 2.
Similarly, the broadly and narrowly neutralizing groups were compared for duration of infection (estimated) and age at acquisition (estimated) in both the full
CHCVcohort (C andE) and the gt1 subgroup (D and F).Note that no datawere available for 6 broadly and 10 narrowly neutralizing individuals in the full CHCV
cohort and 4 broadly and 4 narrowly neutralizing individuals in the gt1 subgroup. Statistical comparisons between the groups were conducted using the
Mann-Whitney U test.
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tween neutralization breadth and reduced fibrosis remained sig-
nificant when corrected for age. There is already evidence that
those infected when they are older have a more rapid disease pro-
gression (49) and that the B cell repertoire narrows with age (50).
Therefore, this may also reflect an effect of aging on NAb re-
sponses.
Although the association between the neutralization breadth
for panel Gt1 and host factors was clear, the association was not as
apparent as that for panel XG. It is not clear from our data if the
associations are indeed gt1 specific or are simply caused by limi-
tations due to the smaller numbers of genotypes used to determine
breadth in the cross-genotypic panel. Although there was a signif-
icant correlation between the numbers ofHCVpp isolates neutral-
ized in both panels, some individuals who had narrow cross-ge-
notypic neutralization profiles showed broad neutralization
activity against panel Gt1, suggesting that some bNAbsmay be gt1
specific.
No association between the levels of E1E2 binding and fibrosis
was found. Unlike an earlier study (51), we found no relationship
between the binding of antibody to the autologous genotype and
clinical outcomes, although there was a trend toward cirrhosis in
gt1-infected individuals with poor binding to gt1a E1E2 (P 0.10;
data not shown). Combined with the neutralization panel data,
this suggests that if antienvelope antibodies do have a protective
effect, this is most marked where the antibodies target regions
necessary for virus entry.
We have demonstrated that an NAb response is not closely
correlated with the extent of patient IgG binding to the whole
E1E2molecule, suggesting that the antibodies of some individuals
preferentially target important neutralization epitopes. Our data
also suggest that the antibodies of those gt1-infected individuals
who mount a broadly neutralizing response are effectively di-
rected at more than one neutralizing domain on E2. In contrast,
the antibodies of those with a narrower neutralizing response ap-
pear to target only one region, that recognized by the HMAbHC-
11. It is possible, however, that the samples from individuals
with narrow neutralizing responses do contain antibodies that
target other neutralizing epitopes, albeit they are present at a
lower concentration or have a lower affinity than the antibodies
found in the broadly neutralizing group. Previous studies have
shown that different regions of E2 interact to prevent neutral-
ization; therefore, it is likely that an antibody response inter-
fering with multiple regions of E2 may be more effective than a
response targeting one epitope alone (52). Furthermore,
Carlsen et al. recently showed synergy in neutralization using a
combination of two antibodies against different domains (53).
Our identification of the epitopes targeted was constrained by
the panel of monoclonal antibodies used. However, alternative
methods, such as peptide and phage display capture, have a
limited ability to detect antibodies directed at discontinuous
epitopes (21); therefore, our data are a valuable complement to
information from these studies.
While there aremany possible explanations for why antibodies
from individuals might preferentially respond to particular
epitopes, we have confirmed that SNP rs2395522 in the HLA-
DQB1 gene is associated with the development of bNAbs in gt1-
FIG 6 Association of the rs2395522 SNP genotype with breadth of neutralization and liver fibrosis. All individuals in the CHCV patient cohort were typed for
HLA-DQB1 SNP rs2395522. The Mann-Whitney U test was used to compare the SNP type with the number of HCVpp neutralized in panel XG (A) and panel
Gt1 (C). Similarly, the SNP type was compared to the level of liver fibrosis, as measured by transient elastography, for the whole CHCV patient cohort (B) or the
gt1 subgroup (D) by the Mann-Whitney U test.
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infected patients (12). TheHLA-DQB1 genotype has already been
identified to be one of the host factors that influences the out-
come of HCV infection in Caucasian populations (54). This
may be due to a restriction in antigen-presenting cell presen-
tation of epitopes to CD4 cells or may involve another mecha-
nism. In contrast, we did not observe an association between
this SNP and the ability to neutralize pseudoparticles of other
genotypes. In particular, there was no association between the
SNP and the ability of IgGs from gt3-infected individuals to
neutralize our standard gt3a HCVpp (P  0.45; data not
shown). This may be due to the limitations of testing one gt3
isolate; alternatively, it is possible that other HLA genes could
be more important for adaptive responses to infections with
other genotypes. Further studies will be required to distinguish
between these possibilities.
Our study demonstrates that broad anti-HCV neutralizing re-
sponses are associatedwith lower levels of liver fibrosis, raising the
possibility for a protective role in chronic infection. Our data also
show strong indications that potent neutralizing responses target
multiple key regions of E2 rather than a single epitope. This has
significant implications for HCV vaccine design, suggesting that a
successful vaccine must induce NAbs to different regions of E2. If
we aim to produce a universally protective vaccine against HCV, a
deeper understanding of the role of the host genotype and the
epitope sequence presented in determining the breadth of the an-
tibody response requires further exploration with a wider range of
isolates of different genotypes before vaccine candidates may be
tested on a wider scale.
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